We believe that constant research and innovation is crucial for the patient’s health care.

Together with our network of international partners, we consider it essential to fully investigate cannabis-based medicine in order to understand their mode of action. Based on this research, we are constantly improving our product-portfolio and developing new preparations made from the cannabis plant. We have the ambition to provide patients, with the best possible cannabinoid-treatment and provide physicians and pharmacists with education about the cannabis-plant.

Our International Network of R&D partners

Connect 4

Connect 4 is founding partner of CanPharma and is extending our expertise, when it comes to questions regarding market access for pharmaceuticals and medical devices. Among others Connect 4 has years of experiences in the fields of regulatory affairs, market intelligence, market entry and market penetration. Together with the team of Connect 4 we want to expand the product variety on the market with new great cannabis-based-pharmaceuticals.

CBM Labs

Together with CBM Labs, we are focusing on the bio-synthetic production of cannabinoids. CBM Labs is based in the Netherlands and already filed in several patents in order to develop formulations based on cannabinoids. Furthermore, CanPharma will provide CBM Labs with cannabis-based pharmaceuticals for research purposes and CBM Labs will support CanPharma to improve the quality of its product varieties to ensure patient-oriented medicine.


Military Laboratory

It is intended that CanPharma Portugal and the Portuguese Military Laboratory will cooperate closely in research & development activities in the field of medical cannabis. The Military Laboratory has the technical direction of industrial pharmaceuticals, quality control regarding the production of medicines with GMP certification, and the security of facilities to support CanPharma Portugal in the fulfillment of the internal requirements and the ones from INFARMED.

Fundação AMA

The Association of Friends of Autism (AMA) was created in June 2008, and is a Private Non-Profit Social Solidarity Institution, dedicated exclusively to the problem of Autism Spectrum Disorders. With the support of CanPharma Portugal, the AMA Foundation and Kalapa Clinic, we have initiated a cooperation to conduct studies on the effects of Cannabis-based pharmaceuticals on people with autism in order to compare it with the commonly used medication for autism.


The purpose of the cooperation with FCT is the execution of a joint research and development project in the fields established by the parties. In specific both parties want to use their potential to promote the increase of knowledge of their personnel and training actions that involve, for example, the accomplishment of curricular internships of students of the Masters.

Do you have any questions?

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.




CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg

CanPharma Portugal
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica


Neue Kantstraße 18
14057 Berlin

Gran de Gràcia 15, 1-1
08012 Barcelona